Literature DB >> 3569555

Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication.

J B Josimovich, M A Lavenhar, M M Devanesan, H J Sesta, S A Wilchins, A C Smith.   

Abstract

Controversy over effects of oral contraceptives (OCs) on serum prolactin (PRL) levels from retrospective studies suggested performing a prospective study. Statistical analyses of PRL levels in 552 reproductive-age, nonmedicated women indicated a provisionally lognormal distribution of values less than 15 ng/ml, contaminated by a small number of abnormally high values less than or equal to 90 mg/ml. Truncated samples were used to estimate a "normal range" of PRL levels for three subsets of the study sample, classified according to number of weeks after pregnancy. Fifty-microgram estrogen-containing OCs doubled basal PRL levels at 5 to 8 weeks in those whose initial control values fell below 15 ng/ml, but the PRL elevation was no longer evident at 6 months of drug use. These OCs induced a small but significant lowering of PRL at 5 to 8 weeks in those with control levels of 15 ng/ml or higher. Thirty-five-microgram estrogen-containing OCs failed to alter PRL levels at 5 to 8 weeks in those with control values less than 15 ng/ml.

Entities:  

Keywords:  Biology; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Methods; Data Analysis; Endocrine System; Examinations And Diagnoses; Family Planning; Gonadotropins; Gonadotropins, Pituitary; Hormones; Laboratory Examinations And Diagnoses; Oral Contraceptives; Physiology; Pituitary Hormones; Prolactin--analysis; Puerperium; Reproduction; Reproductive Control Agents; Research Methodology

Mesh:

Substances:

Year:  1987        PMID: 3569555

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  6 in total

Review 1.  Pharmacologic resistance in prolactinoma patients.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Estradiol-modified prolactin secretion independently of action potentials and Ca2+ and blockade of outward potassium currents in GH3 cells.

Authors:  Manuel Sánchez; Lorena Suárez; Begoña Cantabrana; Javier Bordallo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-10-17       Impact factor: 3.000

3.  Macroprolactinemia in hyperprolactinemic infertile women.

Authors:  Krithika Thirunavakkarasu; Pinaki Dutta; Subbiah Sridhar; Lakhbir Dhaliwal; G R V Prashad; Shalini Gainder; Naresh Sachdeva; Anil Bhansali
Journal:  Endocrine       Date:  2013-03-30       Impact factor: 3.633

Review 4.  Diagnosis and management of hyperprolactinemia.

Authors:  Omar Serri; Constance L Chik; Ehud Ur; Shereen Ezzat
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

Review 5.  Drugs and prolactin.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

6.  Rethinking the stalk effect: a new hypothesis explaining suprasellar tumor-induced hyperprolactinemia.

Authors:  Donal C Skinner
Journal:  Med Hypotheses       Date:  2008-11-22       Impact factor: 1.538

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.